EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors

Ana Corrionero iD, Xiaohu Zhang, Patricia Alfonso, Patrick J Morris iD, Carleen Klumpp-Thomas, Christopher Melani iD, Crystal McKnight, James D Phelan, David Holland, Kelli Wilson iD, Scott B Hoyt iD, Mark Roschewski und 5 weitere

ACS Pharmacology & Translational Science · 12.12.2025 · 8 (12) · 4312-4325

DOI: 10.1021/acsptsci.5c00412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 18.11.2025. Verfasst von Ana Corrionero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Enzymlogic S.L., C/Grisolía 2, Tres Cantos, 28760 Madrid, Spain. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, National Center for Advancing Translational Sciences, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibitors of the Bruton's tyrosine kinase (BTK) are of broad utility in the treatment of multiple diseases including several B-cell malignancies via effective blockade of oncogenic B-cell receptor (BCR) signaling. BTK is a cytoplasmic tyrosine kinase which harbors a targetable cysteine residue (Cys481) and the majority of BTK inhibitors are covalent modifiers directed at this position. Despite possessing a common mechanism of action, BTK inhibitors differ in key attributes including off-target kinome profiles, tolerability, pharmacokinetics and the underlying BTK inhibition kinetics. These characteristics play a significant role in the ultimate utility of these drugs. Herein, we compare several clinically active BTK inhibitors in biochemical and in vitro assays to gain a broader appreciation of the similarities and differences that govern the success of this important drug class. The combined datasets highlight that each agent has excellent on-target potency and good BTK selectivity. The data further suggests an association between optimized BTK inhibition kinetics and in vitro cytotoxicity profiles.

Schlagwörter

Stichwörter der Autor:innen

B-cell receptorBTK inhibitorscovalent inhibitorsenzyme inhibition kineticskinetic selectivitylymphoma

Autor:innen und Institutionen

  • Enzymlogic S.L., C/Grisolía 2, Tres Cantos, 28760 Madrid, Spain.
  • Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • Center for Advanced Study of Drug Action, Department of Chemistry, Stony Brook University, Stony Brook, New York 11794, United States.
  • Department of Biomedical Genetics, University of Rochester, Rochester, New York 14642, United States.

ORCID-Profile: Ana Corrionero, Patrick J Morris, Christopher Melani, Kelli Wilson, Scott B Hoyt, Peter J Tonge, Craig J Thomas

Förderung

  • NIGMS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Cancer Institute
  • National Institute of General Medical Sciences
  • Centro para el Desarrollo Tecnol?gico Industrial

Zitieren

APA

Corrionero, A., Zhang, X., Alfonso, P., Morris, P. J., Klumpp-Thomas, C., Melani, C., McKnight, C., Phelan, J. D., Holland, D., Wilson, K., Hoyt, S. B., Roschewski, M., Tonge, P. J., Wilson, W., Ceribelli, M., Staudt, L. M., & Thomas, C. J. (2025). An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. ACS Pharmacology & Translational Science, 8(12), 4312-4325. https://doi.org/10.1021/acsptsci.5c00412

Vancouver

Corrionero A, Zhang X, Alfonso P, Morris PJ, Klumpp-Thomas C, Melani C, et al. An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. ACS Pharmacology & Translational Science. 2025;8(12):4312-4325. doi:10.1021/acsptsci.5c00412

BibTeX
@article{Corrionero2025,
  author = {Corrionero, Ana and Zhang, Xiaohu and Alfonso, Patricia and Morris, Patrick J and Klumpp-Thomas, Carleen and Melani, Christopher and McKnight, Crystal and Phelan, James D and Holland, David and Wilson, Kelli and Hoyt, Scott B and Roschewski, Mark and Tonge, Peter J and Wilson, Wyndham and Ceribelli, Michele and Staudt, Louis M and Thomas, Craig J},
  title = {An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors},
  journal = {ACS Pharmacology & Translational Science},
  year = {2025},
  volume = {8},
  number = {12},
  pages = {4312--4325},
  doi = {10.1021/acsptsci.5c00412}
}
Kostenlos starten →